Cite
Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine.
MLA
Horgan, Denis, et al. “Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine.” Cancers, vol. 13, no. 3, Feb. 2021, p. 583. EBSCOhost, https://doi.org/10.3390/cancers13030583.
APA
Horgan, D., Ciliberto, G., Conte, P., Curigliano, G., Seijo, L., Montuenga, L. M., Garassino, M., Penault-Llorca, F., Galli, F., Ray-Coquard, I., Querleu, D., Riegman, P., Kerr, K., Van Poppel, H., Bjartell, A., Codacci-Pisanelli, G., Koeva-Balabanova, J., Paradiso, A., Maravic, Z., & Fotaki, V. (2021). Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. Cancers, 13(3), 583. https://doi.org/10.3390/cancers13030583
Chicago
Horgan, Denis, Gennaro Ciliberto, Pierfranco Conte, Giuseppe Curigliano, Luis Seijo, Luis M. Montuenga, Marina Garassino, et al. 2021. “Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine.” Cancers 13 (3): 583. doi:10.3390/cancers13030583.